These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 28247199)

  • 1. Cost Effectiveness of Genotype-Guided Warfarin Dosing in Patients with Mechanical Heart Valve Replacement Under the Fee-for-Service System.
    Kim DJ; Kim HS; Oh M; Kim EY; Shin JG
    Appl Health Econ Health Policy; 2017 Oct; 15(5):657-667. PubMed ID: 28247199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation.
    Patrick AR; Avorn J; Choudhry NK
    Circ Cardiovasc Qual Outcomes; 2009 Sep; 2(5):429-36. PubMed ID: 20031873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation.
    You JH; Tsui KK; Wong RS; Cheng G
    PLoS One; 2012; 7(6):e39640. PubMed ID: 22745801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation.
    Verhoef TI; Redekop WK; Veenstra DL; Thariani R; Beltman PA; van Schie RM; de Boer A; Maitland-van der Zee AH;
    Pharmacogenomics; 2013 Jun; 14(8):869-83. PubMed ID: 23746182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: a cost-effectiveness analysis.
    You JH
    Pharmacogenet Genomics; 2014 Jan; 24(1):6-14. PubMed ID: 24168919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses.
    Li X; Tse VC; Lau WC; Cheung BM; Lip GY; Wong IC; Chan EW
    PLoS One; 2016; 11(6):e0157129. PubMed ID: 27362421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.
    Eckman MH; Rosand J; Greenberg SM; Gage BF
    Ann Intern Med; 2009 Jan; 150(2):73-83. PubMed ID: 19153410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J; Delaitre O; Hammès F; de Pouvourville G
    Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden.
    Verhoef TI; Redekop WK; Langenskiold S; Kamali F; Wadelius M; Burnside G; Maitland-van der Zee AH; Hughes DA; Pirmohamed M
    Pharmacogenomics J; 2016 Oct; 16(5):478-84. PubMed ID: 27272045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation.
    Wang Y; Xie F; Kong MC; Lee LH; Ng HJ; Ko Y
    Cardiovasc Drugs Ther; 2014 Dec; 28(6):575-85. PubMed ID: 25319314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation.
    Leey JA; McCabe S; Koch JA; Miles TP
    Am J Geriatr Pharmacother; 2009 Aug; 7(4):197-203. PubMed ID: 19766951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis.
    Quinn RR; Naimark DM; Oliver MJ; Bayoumi AM
    Am J Kidney Dis; 2007 Sep; 50(3):421-32. PubMed ID: 17720521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients.
    Nguyen E; Egri F; Mearns ES; White CM; Coleman CI
    Pharmacotherapy; 2016 May; 36(5):488-95. PubMed ID: 27015873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control.
    Janzic A; Kos M
    Pharmacoeconomics; 2015 Apr; 33(4):395-408. PubMed ID: 25512096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation.
    Lanitis T; Kongnakorn T; Jacobson L; De Geer A
    Thromb Res; 2014 Aug; 134(2):278-87. PubMed ID: 24935675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
    Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of warfarin care bundles and novel oral anticoagulants for stroke prevention in patients with atrial fibrillation in Thailand.
    Ng SS; Nathisuwan S; Phrommintikul A; Chaiyakunapruk N
    Thromb Res; 2020 Jan; 185():63-71. PubMed ID: 31770689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling the cost-effectiveness of pharmacist-managed anticoagulation service for older adults with atrial fibrillation in Singapore.
    Chua WB; Cheen HH; Kong MC; Chen LL; Wee HL
    Int J Clin Pharm; 2016 Oct; 38(5):1230-40. PubMed ID: 27461367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis.
    You JH
    Pharmacogenomics; 2015; 16(10):1089-100. PubMed ID: 26230572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia.
    Ademi Z; Pasupathi K; Liew D
    Eur J Prev Cardiol; 2015 Mar; 22(3):344-53. PubMed ID: 24281250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.